{"transactions":[{"id":3518151,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":23074,"kind":"person","name":"Friedl-Naderer Johanna","position":1,"cik":"0001915598","reported_name":"Friedl-Naderer Johanna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-09-08T20:15:26.000Z","date":"2026-09-08","kind":"sale","planned":true,"acquired":false,"shares":185,"price":18.88,"value":3492.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.77 to $18.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes 102,966 unvested RSUs."}],"balance_after":152897,"source":{"system":"sec-edgar","filing":"0001915598-26-000005","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1915598/000191559826000005/ownership.xml","form_type":"4"}},{"id":3518150,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":23074,"kind":"person","name":"Friedl-Naderer Johanna","position":1,"cik":"0001915598","reported_name":"Friedl-Naderer Johanna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-09-08T20:15:26.000Z","date":"2026-09-04","kind":"sale","planned":true,"acquired":false,"shares":900,"price":24.35,"value":21915.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 3, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $24.29 to $24.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."}],"balance_after":153082,"source":{"system":"sec-edgar","filing":"0001915598-26-000005","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1915598/000191559826000005/ownership.xml","form_type":"4"}},{"id":686095,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":23074,"kind":"person","name":"Friedl-Naderer Johanna","position":1,"cik":"0001915598","reported_name":"Friedl-Naderer Johanna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-08-17T20:08:51.000Z","date":"2026-08-13","kind":"sale","planned":true,"acquired":false,"shares":226,"price":26.28,"value":5939.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on February 12, 2026. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.17 to $26.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 119,928 unvested RSUs."}],"balance_after":153982,"source":{"system":"sec-edgar","filing":"0001915598-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1915598/000191559826000004/ownership.xml","form_type":"4"}},{"id":735076,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":23074,"kind":"person","name":"Friedl-Naderer Johanna","position":1,"cik":"0001915598","reported_name":"Friedl-Naderer Johanna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-06-17T20:07:50.000Z","date":"2026-06-16","kind":"sale","planned":true,"acquired":false,"shares":145,"price":18.33,"value":2657.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.01 to $18.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 123,678 unvested RSUs."}],"balance_after":154208,"source":{"system":"sec-edgar","filing":"0001915598-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1915598/000191559826000002/ownership.xml","form_type":"4"}},{"id":779836,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":23074,"kind":"person","name":"Friedl-Naderer Johanna","position":1,"cik":"0001915598","reported_name":"Friedl-Naderer Johanna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-05-14T20:05:18.000Z","date":"2026-05-13","kind":"sale","planned":true,"acquired":false,"shares":228,"price":18.36,"value":4186.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on February 12, 2026. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.20 to $18.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 126,040 unvested RSUs."}],"balance_after":154353,"source":{"system":"sec-edgar","filing":"0001193125-26-223984","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1915598/000119312526223984/ownership.xml","form_type":"4"}},{"id":856955,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":23074,"kind":"person","name":"Friedl-Naderer Johanna","position":1,"cik":"0001915598","reported_name":"Friedl-Naderer Johanna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-03-06T21:10:20.000Z","date":"2026-03-05","kind":"sale","planned":true,"acquired":false,"shares":148,"price":14.9,"value":2205.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 129,790 unvested RSUs."}],"balance_after":154581,"source":{"system":"sec-edgar","filing":"0001193125-26-096523","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1915598/000119312526096523/ownership.xml","form_type":"4"}},{"id":902230,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":23074,"kind":"person","name":"Friedl-Naderer Johanna","position":1,"cik":"0001915598","reported_name":"Friedl-Naderer Johanna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-02-17T22:09:42.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on February 12, 2026. The shares underlying the option are scheduled to vest over four years in equal monthly installments through February 12, 2030."}],"balance_after":90000,"derivative":{"exercise_price":16,"expiration_date":"2036-02-11","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001193125-26-055063","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1915598/000119312526055063/ownership.xml","form_type":"4"}},{"id":902229,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":23074,"kind":"person","name":"Friedl-Naderer Johanna","position":1,"cik":"0001915598","reported_name":"Friedl-Naderer Johanna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:09:42.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of Common Stock issuable under 60,000 restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on May 12, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 132,152 unvested RSUs."}],"balance_after":154729,"source":{"system":"sec-edgar","filing":"0001193125-26-055063","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1915598/000119312526055063/ownership.xml","form_type":"4"}},{"id":979638,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":23074,"kind":"person","name":"Friedl-Naderer Johanna","position":1,"cik":"0001915598","reported_name":"Friedl-Naderer Johanna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-12-05T21:08:40.000Z","date":"2025-12-05","kind":"sale","planned":true,"acquired":false,"shares":144,"price":20.72,"value":2983.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.58 to $20.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 72,152 unvested RSUs."}],"balance_after":94729,"source":{"system":"sec-edgar","filing":"0001193125-25-309636","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1915598/000119312525309636/ownership.xml","form_type":"4"}},{"id":1046351,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":23074,"kind":"person","name":"Friedl-Naderer Johanna","position":1,"cik":"0001915598","reported_name":"Friedl-Naderer Johanna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-09-08T20:06:22.000Z","date":"2025-09-05","kind":"sale","planned":true,"acquired":false,"shares":144,"price":13.41,"value":1931.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 74,514 unvested RSUs."}],"balance_after":94873,"source":{"system":"sec-edgar","filing":"0000950170-25-113545","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1915598/000095017025113545/ownership.xml","form_type":"4"}},{"id":1046350,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":23074,"kind":"person","name":"Friedl-Naderer Johanna","position":1,"cik":"0001915598","reported_name":"Friedl-Naderer Johanna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-09-08T20:06:22.000Z","date":"2025-09-04","kind":"sale","planned":true,"acquired":false,"shares":894,"price":13.27,"value":11863.38,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 3, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $13.08 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."}],"balance_after":95017,"source":{"system":"sec-edgar","filing":"0000950170-25-113545","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1915598/000095017025113545/ownership.xml","form_type":"4"}},{"id":1084936,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":23074,"kind":"person","name":"Friedl-Naderer Johanna","position":1,"cik":"0001915598","reported_name":"Friedl-Naderer Johanna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-07-18T21:21:09.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":51255,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on July 16, 2025 (the \"Grant Date\"). The shares underlying the option are scheduled to vest over three years, with 50% of the shares underlying the grant vesting 18 months after the Grant Date and with the balance of the shares underlying the grant vesting in equal quarterly installments thereafter; provided that such option shall not be exercisable unless and until (i) the average closing price of the common stock on the Nasdaq Global Select Market over a 20 consecutive trading day period equals or exceeds $20.00 per share at any time during the three-year period following the Grant Date (the \"Performance Period\") or (ii) a Change in Control (as defined in the Issuer's Amended and Restated Executive Severance and Change in Control Benefits Plan) is consummated during the Performance Period pursuant to which a third party acquires the common stock for a price per share that the Board of Directors of the Issuer determines equals or exceeds $20.00 per share."}],"balance_after":51255,"derivative":{"exercise_price":9.33,"expiration_date":"2035-07-15","underlying":"Common Stock","underlying_shares":51255},"source":{"system":"sec-edgar","filing":"0000950170-25-097007","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1915598/000095017025097007/ownership.xml","form_type":"4"}},{"id":1120367,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":23074,"kind":"person","name":"Friedl-Naderer Johanna","position":1,"cik":"0001915598","reported_name":"Friedl-Naderer Johanna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-06-06T20:03:04.000Z","date":"2025-06-05","kind":"sale","planned":true,"acquired":false,"shares":146,"price":13.35,"value":1949.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $13.21 to $13.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 91,476 unvested RSUs."}],"balance_after":95911,"source":{"system":"sec-edgar","filing":"0000950170-25-083033","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1915598/000095017025083033/ownership.xml","form_type":"4"}},{"id":1208401,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":23074,"kind":"person","name":"Friedl-Naderer Johanna","position":1,"cik":"0001915598","reported_name":"Friedl-Naderer Johanna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-03-13T20:13:26.000Z","date":"2025-03-13","kind":"sale","planned":true,"acquired":false,"shares":143,"price":12.12,"value":1733.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 93,838 unvested RSUs."}],"balance_after":96057,"source":{"system":"sec-edgar","filing":"0000950170-25-038750","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1915598/000095017025038750/ownership.xml","form_type":"4"}},{"id":1340976,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":23074,"kind":"person","name":"Friedl-Naderer Johanna","position":1,"cik":"0001915598","reported_name":"Friedl-Naderer Johanna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock option (right to buy)","published_at":"2024-12-06T21:05:18.000Z","date":"2024-12-04","kind":"grant","planned":false,"acquired":true,"shares":60300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on December 4, 2024. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 4, 2028."}],"balance_after":60300,"derivative":{"exercise_price":29.44,"expiration_date":"2034-12-03","underlying":"Common Stock","underlying_shares":60300},"source":{"system":"sec-edgar","filing":"0000950170-24-134078","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1915598/000095017024134078/ownership.xml","form_type":"4"}},{"id":1340975,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":23074,"kind":"person","name":"Friedl-Naderer Johanna","position":1,"cik":"0001915598","reported_name":"Friedl-Naderer Johanna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-12-06T21:05:18.000Z","date":"2024-12-04","kind":"grant","planned":false,"acquired":true,"shares":37800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of Common Stock issuable under 37,800 restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 4, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 96,200 unvested RSUs."}],"balance_after":96200,"source":{"system":"sec-edgar","filing":"0000950170-24-134078","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1915598/000095017024134078/ownership.xml","form_type":"4"}},{"id":1418223,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":23074,"kind":"person","name":"Friedl-Naderer Johanna","position":1,"cik":"0001915598","reported_name":"Friedl-Naderer Johanna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-03T22:16:28.000Z","date":"2024-09-03","kind":"grant","planned":false,"acquired":true,"shares":185300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on September 3, 2024. The shares underlying the option are scheduled to vest over four years, with 25% of the shares vesting on September 3, 2025, and the remainder vesting in equal quarterly installments thereafter, subject to continuous service."}],"balance_after":185300,"derivative":{"exercise_price":31.94,"expiration_date":"2034-09-02","underlying":"Common Stock","underlying_shares":185300},"source":{"system":"sec-edgar","filing":"0000950170-24-103033","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1915598/000095017024103033/ownership.xml","form_type":"4"}},{"id":1418222,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":23074,"kind":"person","name":"Friedl-Naderer Johanna","position":1,"cik":"0001915598","reported_name":"Friedl-Naderer Johanna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-09-03T22:16:28.000Z","date":"2024-09-03","kind":"grant","planned":false,"acquired":true,"shares":58400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of Common Stock issuable under 58,400 restricted stock units (\"RSU\"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal annual installments over four years with the first installment vesting on September 3, 2025."}],"balance_after":58400,"source":{"system":"sec-edgar","filing":"0000950170-24-103033","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1915598/000095017024103033/ownership.xml","form_type":"4"}},{"id":1967083,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":23074,"kind":"person","name":"Friedl-Naderer Johanna","position":1,"cik":"0001915598","reported_name":"Friedl-Naderer Johanna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-03-07T19:04:22.000Z","date":"2023-03-03","kind":"sale","acquired":false,"shares":1482,"price":22.82,"value":33819.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units."}],"balance_after":148518,"source":{"system":"sec-edgar","filing":"0001209191-23-016629","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1915598/000120919123016629/doc4.xml","form_type":"4"}},{"id":1994291,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":23074,"kind":"person","name":"Friedl-Naderer Johanna","position":1,"cik":"0001915598","reported_name":"Friedl-Naderer Johanna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-25T01:27:45.000Z","date":"2023-02-22","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the stock option vest and become exercisable on February 22, 2024, and the remainder vest in 36 equal monthly installments thereafter."}],"balance_after":70000,"derivative":{"exercise_price":27.01,"expiration_date":"2033-02-21","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001209191-23-012991","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1915598/000120919123012991/doc4.xml","form_type":"4"}},{"id":1994290,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":23074,"kind":"person","name":"Friedl-Naderer Johanna","position":1,"cik":"0001915598","reported_name":"Friedl-Naderer Johanna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-02-25T01:27:45.000Z","date":"2023-02-22","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan."}],"balance_after":150000,"source":{"system":"sec-edgar","filing":"0001209191-23-012991","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1915598/000120919123012991/doc4.xml","form_type":"4"}},{"id":2345567,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":23074,"kind":"person","name":"Friedl-Naderer Johanna","position":1,"cik":"0001915598","reported_name":"Friedl-Naderer Johanna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer, Global"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-08T16:35:47.000Z","date":"2022-03-02","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the stock option vest and become exercisable on March 2, 2023, and the remainder vest in 36 equal monthly installments thereafter."}],"balance_after":45000,"derivative":{"exercise_price":24.13,"expiration_date":"2032-03-01","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001209191-22-016929","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1915598/000120919122016929/doc4.xml","form_type":"4"}},{"id":2345566,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":23074,"kind":"person","name":"Friedl-Naderer Johanna","position":1,"cik":"0001915598","reported_name":"Friedl-Naderer Johanna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer, Global"}}],"security":"Common Stock","published_at":"2022-03-08T16:35:47.000Z","date":"2022-03-02","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan."}],"balance_after":90000,"source":{"system":"sec-edgar","filing":"0001209191-22-016929","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1915598/000120919122016929/doc4.xml","form_type":"4"}}]}